cbdmd inc - YCBD

YCBD

Close Chg Chg %
1.11 -0.03 -2.25%

Closed Market

1.09

-0.03 (2.25%)

Volume: 1.22M

Last Updated:

Jan 8, 2026, 3:59 PM EDT

Company Overview: cbdmd inc - YCBD

YCBD Key Data

Open

$1.08

Day Range

1.04 - 1.13

52 Week Range

0.47 - 6.54

Market Cap

$10.30M

Shares Outstanding

8.96M

Public Float

8.29M

Beta

2.10

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$3.92

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

29.45M

 

YCBD Performance

1 Week
 
-18.52%
 
1 Month
 
80.33%
 
3 Months
 
-10.57%
 
1 Year
 
-75.58%
 
5 Years
 
-99.91%
 

YCBD Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 1
Full Ratings ➔

About cbdmd inc - YCBD

cbdMD, Inc. engages in the business of operating cannabidiol brands such as Paw cannabidiol and cbdMD botanicals. Its product categories include CBD tinctures, gummies, topical, and bath bombs. The company was founded on March 17, 2015 and is headquartered in Charlotte, NC.

YCBD At a Glance

cbdMD, Inc.
2101 Westinghouse Boulevard
Charlotte, North Carolina 28273
Phone 1-704-445-3060 Revenue 19.19M
Industry Pharmaceuticals: Other Net Income -2,040,902.00
Sector Health Technology Employees 42
Fiscal Year-end 09 / 2026
View SEC Filings

YCBD Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 0.254
Price to Book Ratio 1.494
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -9.235
Enterprise Value to Sales 0.176
Total Debt to Enterprise Value 0.23

YCBD Efficiency

Revenue/Employee 456,915.905
Income Per Employee -48,592.905
Receivables Turnover 18.437
Total Asset Turnover 1.828

YCBD Liquidity

Current Ratio 2.051
Quick Ratio 1.129
Cash Ratio 0.708

YCBD Profitability

Gross Margin 56.497
Operating Margin -11.269
Pretax Margin -10.635
Net Margin -10.635
Return on Assets -19.436
Return on Equity -44.418
Return on Total Capital -25.497
Return on Invested Capital -44.418

YCBD Capital Structure

Total Debt to Total Equity 10.77
Total Debt to Total Capital 9.723
Total Debt to Total Assets 7.469
Long-Term Debt to Equity N/A
Long-Term Debt to Total Capital N/A
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Cbdmd Inc - YCBD

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
35.40M 24.16M 19.48M 19.19M
Sales Growth
-20.41% -31.77% -19.35% -1.50%
Cost of Goods Sold (COGS) incl D&A
14.90M 11.12M 8.64M 8.35M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
2.97M 2.93M 1.82M 1.80M
Depreciation
2.09M 1.53M 1.12M 1.03M
Amortization of Intangibles
884.38K 1.40M 697.51K 765.08K
COGS Growth
-3.95% -25.38% -22.33% -3.34%
Gross Income
20.50M 13.04M 10.85M 10.84M
Gross Income Growth
-29.22% -36.42% -16.81% -0.03%
Gross Profit Margin
+57.91% +53.97% +55.67% +56.50%
2022 2023 2024 2025 5-year trend
SG&A Expense
37.81M 22.31M 14.04M 13.00M
Research & Development
- - - -
-
Other SG&A
37.81M 22.31M 14.04M 13.00M
SGA Growth
-22.17% -41.01% -37.08% -7.34%
Other Operating Expense
- - - -
-
Unusual Expense
53.08M 13.03M 481.05K (87.38K)
EBIT after Unusual Expense
(70.39M) (22.30M) (3.67M) (2.08M)
Non Operating Income/Expense
- 310.92K (636.30K) 34.31K
Non-Operating Interest Income
- 16.25K 63.70K 34.31K
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - - 29.51K
-
Interest Expense Growth
- - - -
-
Gross Interest Expense
- - - 29.51K
-
Interest Capitalized
- - - -
-
Pretax Income
(70.08M) (22.94M) (3.70M) (2.04M)
Pretax Income Growth
-188.53% +67.27% +83.87% +44.84%
Pretax Margin
-197.96% -94.96% -18.99% -10.63%
Income Tax
- - - -
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(70.08M) (22.94M) (3.70M) (2.04M)
Minority Interest Expense
- - - -
-
Net Income
(70.08M) (22.94M) (3.70M) (2.04M)
Net Income Growth
-199.57% +67.27% +83.87% +44.84%
Net Margin Growth
-197.96% -94.96% -18.99% -10.63%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(70.08M) (22.94M) (3.70M) (2.04M)
Preferred Dividends
4.00M 4.00M 4.00M 2.33M
Net Income Available to Common
(74.09M) (26.94M) (7.70M) (4.38M)
EPS (Basic)
-446.3712 -106.5715 -14.2916 -1.0877
EPS (Basic) Growth
-162.51% +76.12% +86.59% +92.39%
Basic Shares Outstanding
165.97K 252.79K 539.07K 4.02M
EPS (Diluted)
-446.3712 -106.5715 -14.2916 -1.0877
EPS (Diluted) Growth
-162.51% +76.12% +86.59% +92.39%
Diluted Shares Outstanding
165.97K 252.79K 539.07K 4.02M
EBITDA
(14.34M) (6.34M) (1.37M) (366.67K)
EBITDA Growth
+17.41% +55.78% +78.41% +73.22%
EBITDA Margin
-40.51% -26.25% -7.03% -1.91%

Snapshot

Average Recommendation BUY Average Target Price 2.00
Number of Ratings 1 Current Quarters Estimate -0.07
FY Report Date 03 / 2026 Current Year's Estimate -0.22
Last Quarter’s Earnings -0.06 Median PE on CY Estimate N/A
Year Ago Earnings -1.09 Next Fiscal Year Estimate -0.09
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 1 1 1 1
Mean Estimate -0.07 -0.07 -0.22 -0.09
High Estimates -0.07 -0.07 -0.22 -0.09
Low Estimate -0.07 -0.07 -0.22 -0.09
Coefficient of Variance N/A N/A N/A N/A

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 1 1 1
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Cbdmd Inc - YCBD

Date Name Shares Transaction Value
May 21, 2025 Jeffrey Howard Porter Director 1,572 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 21, 2025 Bakari Sellers Director 2,752 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 21, 2025 Scott G. Stephen Director 2,840 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 21, 2025 William F. Raines Director 12,104 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 21, 2025 Sibyl Swift Director 2,573 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 21, 2025 Kevin Roe Director 25,135 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Cbdmd Inc in the News